Page last updated: 2024-12-07

2-methyltryptoline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-methyltryptoline: enzymatic preparation from human brain converts methyltyptamine to methyltryptoline; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID121896
CHEMBL ID69618
CHEBI ID185749
SCHEMBL ID1055807
MeSH IDM0054773

Synonyms (37)

Synonym
2-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole
2-methyl-2,3,4,9-tetrahydro-1h-.beta.-carboline
nsc-683435
NCI60_029908
MLS001049128
smr000386955
OPREA1_539196
nsc683435
inchi=1/c12h14n2/c1-14-7-6-10-9-4-2-3-5-11(9)13-12(10)8-14/h2-5,13h,6-8h2,1h
2-methyltryptoline
CHEMBL69618 ,
CHEBI:185749
13100-00-0
1,2,3,4-tetrahydro-2-methyl-b-carboline
n-methyltetrahydro-beta-carboline
2-methyl-2,3,4,9-tetrahydro-1h-beta-carboline
bdbm50018545
NCGC00246229-01
2-methyltetrahydro-beta-carboline
2-methyl-1,2,3,4-tetrahydro-beta-carboline
2-methyl-9h-1,2,3,4-tetrahydropyrido(3,4-b) indole
HMS2268E23
AKOS006320934
SCHEMBL1055807
1h-pyrido[3,4-b]indole, 2,3,4,9-tetrahydro-2-methyl-
2-methyl-1,2,3,4-tetrahydro-.beta.-carboline
2-methyl-2,3,4,9-tetrahydro-1h-beta-carboline #
2-methyltetrahydro-b-carboline
2-methyl-2,3,4,9-tetrahydro-1h-b-carboline
2-methyl-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole
F1905-8574
DTXSID40156838
2-methyl-1h,2h,3h,4h,9h-pyrido[3,4-b]indole
2,3,4,9-tetrahydro-2-methyl-1h-pyrido[3,4-b]indole, 9ci
2,3,4,9-tetrahydro-2-methyl-1h-pyrido[3,4-b]indole
TQP1342
PD166857
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
beta-carbolinesAny pyridoindole containing a beta-carboline skeleton and their hydrogenated derivatives
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency39.81070.177814.390939.8107AID2147
glucocerebrosidaseHomo sapiens (human)Potency39.81070.01268.156944.6684AID2101
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID540317
gemininHomo sapiens (human)Potency0.81990.004611.374133.4983AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Amine oxidase [flavin-containing] BBos taurus (cattle)Ki400.00000.05401.83906.0000AID126504
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
primary amine oxidase activityAmine oxidase [flavin-containing] BBos taurus (cattle)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] BBos taurus (cattle)
monoamine oxidase activityAmine oxidase [flavin-containing] BBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
mitochondrionAmine oxidase [flavin-containing] BBos taurus (cattle)
mitochondrial outer membraneAmine oxidase [flavin-containing] BBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID126519Rate of oxidation against monoamine oxidase B1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Studies on semirigid tricyclic analogues of the nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
AID402352Cytotoxicity against human A2780 cells2005Journal of natural products, Jun, Volume: 68, Issue:6
Alkaloids and aromatics of Cyathobasis fruticulosa (Bunge) Aellen.
AID61001The maximal DA release induced by perfusion with 10 mM MPP+ (15 min) 1 day after perfusion with the test compound with basal striatal DA (%of basal x10E-3)1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
In vivo intracerebral microdialysis studies in rats of MPP+ analogues and related charged species.
AID126504Binding affinity against Monoamine oxidase B1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Studies on semirigid tricyclic analogues of the nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
AID61002The maximum dopamine release induced by perfusion with the test compound with basal striatal DA (%of basal x10E-3)1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
In vivo intracerebral microdialysis studies in rats of MPP+ analogues and related charged species.
AID127348Binding affinity towards monoaminooxidase Relative to MPTP1993Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20
QSAR's from similarity matrices. Technique validation and application in the comparison of different similarity evaluation methods.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (33)

TimeframeStudies, This Drug (%)All Drugs %
pre-199016 (48.48)18.7374
1990's9 (27.27)18.2507
2000's3 (9.09)29.6817
2010's4 (12.12)24.3611
2020's1 (3.03)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.53

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.53 (24.57)
Research Supply Index3.56 (2.92)
Research Growth Index4.09 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.53)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other34 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]